Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: Assessment of mutational and indirect activation

Annals of Hematology

Volumn 88, Issue 4, 2009, Pages 319-324

  Raepple, D ^a   von Lintig, F ^b   Zemojtel, T ^c   Duchniewicz, M ^a   Jung, A ^d   Lubbert M ^a   Boss, G R ^b   Scheele, J S ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Hematopoietic malignancies; LMWG; Mutation; Oncogenes; Ras; Signal transduction

Indexed keywords

GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; RAS PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC CORRELATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; JUVENILE MYELOMONOCYTIC LEUKEMIA; LYMPHOMA; MOUSE; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; SIGNAL TRANSDUCTION;

DNA MUTATIONAL ANALYSIS; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; LYMPHOMA; MUTATION; MYELOPROLIFERATIVE DISORDERS; ONCOGENES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RAS PROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 60749099164     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0593-6     Document Type: Article

References (35)

1. Fasano O, Aldrich T et al (1984) Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc Natl Acad Sci U S A 81(13):4008-4012. doi: 10.1073/pnas.81.13.4008
2. Guo W, Tang B et al (1998) N-ras mutations in 43 Chinese cases of acute myeloid leukemia. Chin Med J (Engl) 111:343-345
3. Farr C, Gill R et al (1991) Analysis of ras gene mutations in childhood myeloid leukaemia. Br J Haematol 77:323-327. doi: 10.1111/ j.1365-2141.1991.tb08578.x
4. Shih LY, Huang CF et al (2004) Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 18:466-475. doi: 10.1038/sj.leu.2403274
5. Padua RA, Guinn BA et al (1998) RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: A 10-year follow-up. Leukemia 12:887-892. doi: 10.1038/sj.leu.2401044
6. Hunter T (1997) Oncoprotein networks. Cell 88:333-346. doi: 10.1016/ S0092-8674(00)81872-3
7. Tobal K, Pagliuca A et al (1990) Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 4:486-489
8. Kiyoi H, Naoe T et al (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074-3080
9. Rohrschneider LR, Bourette RP et al (1997) Growth and differentiation signals regulated by the M-CSF receptor. Mol Reprod Dev 46:96-103. doi: 10.1002/(SICI)1098-2795(199701)46:1<96::AID-MRD15>3.0.CO;2-1
10. Skorski T, Kanakaraj P et al (1994) Negative regulation of pl20GAP GTPase promoting activity by p210bcr/abl: Implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med 179:1855-1865. doi: 10.1084/jem.179.6.1855
11. Sawyers CL, McLaughlin J et al (1995) Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 181:307-313. doi: 10.1084/jem.181.1.307
12. Golub TR, Barker GF et al (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307-316. doi: 10.1016/ 0092-8674(94)90322-0
13. Golub TR, Goga A et al (1996) Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 16:4107-4116
14. Elmberger PG, Lozano MD et al (1995) Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions. Blood 86:3517-3521
15. Waggott W, Lo YM et al (1995) Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma. Br J Haematol 89:905-907
16. Xu GF, O'Connell P et al (1990) The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62:599-608. doi: 10.1016/ 0092-8674(90)90024-9
17. DeClue JE, Papageorge AG et al (1992) Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265-273. doi: 10.1016/0092-8674(92)90407-4
18. Side L, Taylor B et al (1997) Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 336:1713-1720. doi: 10.1056/ NEJM199706123362404
19. Miyauchi J, Asada M et al (1994) Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood 83:2248-2254
20. Kalra R, Paderanga DC et al (1994) Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 84:3435-3439
21. Tartaglia M, Niemeyer CM et al (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34:148-150. doi: 10.1038/ng1156
22. Kratz CP, Niemeyer CM et al (2005) The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 106:2183-2185. doi: 10.1182/blood-2005-02-0531
23. Pandit B, Sarkozy A et al (2007) Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39(8):1007-1012. doi: 10.1038/ng2073
24. Razzaque MA, Nishizawa T et al (2007) Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 39(8):1013-1017. doi: 10.1038/ng2078
25. Scheele JS, Rhee JM, Boss GR (1995) Determination of absolute amounts of GDP and GTP bound to Ras in mammalian cells: Comparison of parental and ras-overproducing NIH 3T3 fibroblasts. Proc Natl Acad Sci U S A 92:1097-1100. doi: 10.1073/pnas.92.4.1097
26. Von Lintig FC, Huvar I et al (2000) Ras activation in normal white blood cells and childhood acute lymphoblastic leukemia. Clin Cancer Res 6:1804-1810
27. Stites EC, Trampont PC et al (2007) Network analysis of oncogenic Ras activation in cancer. Science 318(5849):463-467. doi: 10.1126/ science.1144642
28. Shen WP, Aldrich TH et al (1987) Expression of normal and mutant ras proteins in human acute leukemia. Oncogene 1:157-165
29. Bernards A, Settleman J (2005) GAPs in growth factor signalling. Growth Factors 23(2):143-149. doi: 10.1080/08977190500130480
30. Gulbins E, Brenner B et al (1996) Activation of the Ras signaling pathway by the CD40 receptor. J Immunol 157:2844-2850
31. Garicochea B, Giorgi R, Odone VF, Dorlhiac-Llacer PE, Bendit I (1998) Mutational analysis of N-RAS and GAP-related domain of the neurofibromatosis type 1 gene in chronic myelogenous leukemia. Leuk Res 22:1003-1007. doi: 10.1016/S0145-2126(98)00076-9
32. Cortes J, Quintás-Cardama A, Garcia-Manero G, O'Brien S, Jones D, Faderl S et al (2007) Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer 110(9):2000-2006. doi: 10.1002/cncr.23006
33. Reichert A, Heisterkamp N, Daley GQ, Groffen J (2001) Treatment of Bcr/ Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood 97:1399-1403. doi: 10.1182/blood.V97.5.1399
34. Halaschek-Wiener J, Wacheck V, Schlagbauer-Wadl H, Wolff K, Kloog Y, Jansen B (2000) A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. Mol Med 6:693-704
35. Scheele JS, Raepple D, Luebbert M (2000) The role of Ras and other low-molecular weight guanine nucleotide (GTP)-binding proteins during hematopoietic cell differentiation. Cell Mol Life Sci 57:1950-1963. doi: 10.1007/PL00000675